Abstract

As a non-invasive method of local and systemic drug delivery, the administration of active pharmaceutical ingredients (APIs) via the pulmonary route represents an ideal approach for the therapeutic treatment of pulmonary diseases. The pulmonary route provides a number of advantages, including the rapid absorption which results from a high level of vascularisation over a large surface area and the successful avoidance of first-pass metabolism. Aerosolization of nanoparticles (NPs) is presently under extensive investigation and exhibits a high potential for targeted delivery of therapeutic agents for the treatment of a wide range of diseases. NPs need to possess specific characteristics to facilitate their transport along the pulmonary tract and appropriately overcome the barriers presented by the pulmonary system. The most challenging aspect of delivering NP-based drugs via the pulmonary route is developing colloidal systems with the optimal physicochemical parameters for inhalation. The physiochemical properties of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) have been investigated as a template for the synthesis of NPs to assist in the formulation of virus-like particles (VLPs) for pharmaceutical delivery, vaccine production and diagnosis assays.

摘要

作为一种局部和全身给药的非侵入性方法，活性药物成分 (API) 的给药通过肺部途径是治疗肺部疾病的理想方法。肺部途径提供了许多优点，包括由于大表面积上的高水平血管形成而导致的快速吸收和成功避免首过代谢。纳米颗粒 (NPs) 的气溶胶化目前正在广泛研究中，并显示出用于治疗多种疾病的靶向递送治疗剂的巨大潜力。NPs 需要具备特定的特性以促进其沿肺道的运输，并适当地克服肺系统的障碍。通过以下方式提供基于 NP 的药物最具挑战性的方面肺部途径正在开发具有最佳吸入物理化学参数的胶体系统。已经研究了严重急性呼吸综合征冠状病毒-2 (SARS-CoV-2) 的理化特性，作为合成 NP 的模板，以帮助配制用于药物递送、疫苗生产和诊断的病毒样颗粒 (VLP)化验。